Merck Expands Life Science Production Capacities in the United States
PR87063
DARMSTADT, Germany, Dec. 7, 2020/PRNewswire=KYODO JBN/--
--Expansions to significantly increase capacity by end of 2021 to meet
unprecedented demand
--Combined expansion of Danvers, Massachusetts, and Jaffrey, New Hampshire, USA
facilities to create nearly 700 new positions
--Business sector's announced 2020 investments total more than € 350 million
Merck, a leading science and technology company, today announced the broadening
of its manufacturing footprint with a combined € 40 million investment at its
production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire,
USA. These sites supply critical products to customers developing lifesaving
therapies, including Covid-19 vaccines, as well as provide products and
services for biopharmaceutical manufacturing. These expansions will
significantly increase capacity and output at these facilities by the end of
2021 and 2022, respectively, and create nearly 700 new manufacturing positions.
Photo: https://mma.prnewswire.com/media/1358444/Merck_Expansions.jpg
"The global coronavirus pandemic has significantly increased demand for our
single-use and virus filtration technologies, which we are supplying to more
than 50 different companies working on Covid-19 vaccine candidates," said Chris
Ross, interim head, Life Science, at Merck. "These investments will strengthen
our global manufacturing footprint, allowing us to meet this unprecedented
demand and help get lifesaving vaccines and therapies to more patients,
faster."
This expansion will add 6,000 square meters of space to the Danvers single-use
assembly operation, adding to the existing 11,000-square-meter facility. The
expansion will add the capacity needed to support the manufacturing of products
across several portfolios, including Merck's Mobius(R) single-use consumables (
). The total investment in Danvers is about € 21 million and will add
approximately 400 jobs throughout 2021.
The Jaffrey expansion plans include adding 2,300 square meters to the existing
24,000-square-meter facility. The additional capacity includes new production
lines and equipment to support the manufacturing of filtration devices and
membrane products, specifically Durapore(R) filters, Express(R) filters (
) and the Viresolve(R) product lines (
). These products are used to ensure the sterility of many lifesaving therapies
and to remove viral contamination for a variety of therapies. The total
investment in Jaffrey is about (EUR) 18.5 million. This expansion is expected
to bring nearly 275 roles by 2022, once the expansion is completed.
These expansions join the Life Science investments announced in 2020 to further
enhance capabilities and capacity in Buchs, Switzerland; Carlsbad, California,
USA; Madison, Wisconsin, USA; and Darmstadt, Germany, broadening the company's
global manufacturing footprint.
More information on the company's contribution to the global Covid-19 response
is available here:
https://www.merckgroup.com/en/company/press/press-kits/corona-pandemic.html
All Merck news release are distributed by email at the same time they become
available on the Merck website. Please go to: www.merckgroup.com/subscribe to
register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare,
life science and performance materials. Around 57,000 employees work to make a
positive difference to millions of people's lives every day by creating more
joyful and sustainable ways to live. From advancing gene editing technologies
and discovering unique ways to treat the most challenging diseases to enabling
the intelligence of devices – the company is everywhere. In 2019, Merck
generated sales of (EUR)16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to
Merck's technological and scientific advances. This is how Merck has thrived
since its founding in 1668. The founding family remains the majority owner of
the publicly listed company. Merck holds the global rights to the Merck name
and brand. The only exceptions are the United States and Canada, where the
business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma
in life science and EMD Performance Materials.
SOURCE: Merck
CONTACT: Karen.tiano@milliporesigma.com
+49-6151-72-44461
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
